These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 34414841)
1. Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe? Shylesh C M S; V S A; S K K; P UD Clin Exp Hypertens; 2022 Jan; 44(1):1-10. PubMed ID: 34414841 [No Abstract] [Full Text] [Related]
2. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. Shukla AK; Banerjee M High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533 [TBL] [Abstract][Full Text] [Related]
3. The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review. Gathiram P; Mackraj I; Moodley J Curr Hypertens Rep; 2021 Mar; 23(4):17. PubMed ID: 33768439 [TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin system at the interface of COVID-19 infection. Gul R; Kim UH; Alfadda AA Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029 [TBL] [Abstract][Full Text] [Related]
5. Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection. Paul D; Mohankumar SK; Thomas RS; Kheng CB; Basavan D Curr Drug Targets; 2022; 23(4):364-372. PubMed ID: 34732115 [TBL] [Abstract][Full Text] [Related]
6. Timing matters in the use of renin-angiotensin system modulators and COVID-related cognitive and cerebrovascular dysfunction. Meier M; Becker S; Levine E; DuFresne O; Foster K; Moore J; Burnett FN; Hermanns VC; Heath SP; Abdelsaid M; Coucha M PLoS One; 2024; 19(7):e0304135. PubMed ID: 39074114 [TBL] [Abstract][Full Text] [Related]
7. Hypertension and COVID-19: Current Evidence and Perspectives. Gallo G; Calvez V; Savoia C High Blood Press Cardiovasc Prev; 2022 Mar; 29(2):115-123. PubMed ID: 35184271 [TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality. Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317 [TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic. Dworakowska D; Grossman AB J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235 [TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19. Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367 [TBL] [Abstract][Full Text] [Related]
11. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911 [TBL] [Abstract][Full Text] [Related]
12. Therapy with RAS inhibitors during the COVID-19 pandemic. Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584 [TBL] [Abstract][Full Text] [Related]
13. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic. Vázquez-Cornejo E Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690 [TBL] [Abstract][Full Text] [Related]
14. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. Edmonston DL; South AM; Sparks MA; Cohen JB Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells. Caputo I; Caroccia B; Frasson I; Poggio E; Zamberlan S; Morpurgo M; Seccia TM; Calì T; Brini M; Richter SN; Rossi GP Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563515 [TBL] [Abstract][Full Text] [Related]
17. COVID-19 and renin-angiotensin system modulators: what do we know so far? de la Cruz A; Ashraf S; Vittorio TJ; Bella JN Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019. Suh SH; Ma SK; Kim SW; Bae EH Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712 [TBL] [Abstract][Full Text] [Related]
19. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension. Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731 [TBL] [Abstract][Full Text] [Related]
20. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Kreutz R; Algharably EAE; Azizi M; Dobrowolski P; Guzik T; Januszewicz A; Persu A; Prejbisz A; Riemer TG; Wang JG; Burnier M Cardiovasc Res; 2020 Aug; 116(10):1688-1699. PubMed ID: 32293003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]